Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD.

Abstract The objectives of this study were to determine the effect of single and repeat dosing with oral ondansetron, a 5-HT3-specific receptor blocker, on the degree and duration of bronchodilation induced by inhaled ipratropium bromide in patients with COPD. Five clinics and university medical centers in four countries participated in the study; 47 patients with COPD were randomized to treatment; 44 completed all treatments. Patients had a baseline (pre-bronchodilator) FEV1>1 L and post-bronchodilator (200 mcg salbutamol) FEV1